Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: A randomized controlled trial
Clinical efficacy of tandospirone augmentation in patients with major depressive disorder: A randomized controlled trial
复制标题
DOI：
10.1046/j.1440-1819.2003.01099.x
复制
发表时间：
2003-04
影响因子：
11.9
通讯作者：
Kazuo Yamada;G. Yagi;S. Kanba
中科院分区：
文献类型：
--
作者：
Kazuo Yamada;G. Yagi;S. Kanba
摘要本文探讨坦度螺酮加用氯丙咪嗪（CMI）治疗36例未经治疗的门诊抑郁症患者的疗效。治疗组12例（T组），对照组12例（D组），治疗组12例（C组）。三个治疗组之间的汉密尔顿抑郁评定量表（17项; HDRS-17）和汉密尔顿焦虑评定量表（14项; HARS-14）评分的改善百分比无统计学显著性差异。然而，在2周时，T组HDRS-17评分的改善百分比倾向于高于D组和C组，尽管三个治疗组之间无统计学显著差异。坦度螺酮的添加未引起血浆催乳素水平的变化或不良事件。这些结果表明，6周的坦度螺酮或地西泮治疗是没有有效的增强重度抑郁症患者的CMI。然而，通过坦度螺酮给药几周来增加抗抑郁药可能会诱导抗抑郁作用的早期表达。
Abstract The purpose of the present paper was to investigate the efficacy of augmentation of clomipramine (CMI) by tandospirone in 36 untreated outpatients with major depressive disorder. Twelve patients were treated with CMI and tandospirone (T group), 12 with CMI and diazepam (D group) and 12 with CMI alone (C group) for 6 weeks. No statistically significant differences in the percentage improvement of the Hamilton Depression Rating Scale (17 items; HDRS‐17) and the Hamilton Anxiety Rating Scale (14 items; HARS‐14) scores were shown among the three treatment groups. However, at 2 weeks, the percentage improvement of HDRS‐17 score in the T group tended to be higher than that in the D and C groups, although there was no statistically significant difference among the three treatment groups. No change in plasma prolactin level or adverse events was induced by the addition of tandospirone. These results suggest that 6 weeks of treatment with tandospirone or diazepam was not effective for augmentation of CMI in major depressive disorder patients. However, augmentation of antidepressants by tandospirone administration for a few weeks might induce early expression of antidepressive effects.